Krystal Biotech, Inc.

NASDAQ:KRYS

Biotechnology

Healthcare
$298.55 +5.66%

+$18.29 today

Market cap
$8.85B
Beta
0.53
P/E (TTM)
44.5
EPS (TTM)
$7.68
52W Low $130.17High $347.67

Volume 0.16M

Average 0.29M

KRYS EBITDA Margin

EBITDA as a percentage of revenue.

Krystal Biotech, Inc.NASDAQ: KRYS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 56.7%

EBITDA Margin was 56.7% in Q2 FY2026, up 6.4 pp from a year earlier. On a trailing-twelve-month basis it was 49.9%, down 0.2 pp year over year.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 6 analysts of 61.4% for the fiscal year ending Dec 2026, up from 50.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
56.7%+2.5 pp QoQ
Last fiscal yearDec 2025
50.4%+12.5 pp YoY
LTMJun 2026
49.9%-0.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.4 pp+6.2 pp-0.3 pp
1 year+12.5 pp+11.0 pp-1.5 pp
3 years—+13.2 pp—
5 years+14.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
50.4%
Year-over-year change
+12.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How KRYS compares with its peers on the latest reported figures

  • KRYS's LTM Jun 2026 EBITDA Margin of 49.9% is the 2nd highest of the 4 companies compared; the peer median is -120.0%.
  • Its year-over-year change of -0.2 pp is the 2nd highest of 3, against a peer median of +53.9 pp.
KRYS Competitors Peer median
EBITDA Margin for KRYS and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026505.0% —+3781.9 pp
KRYSKrystal Biotech, Inc.LTM Jun 202649.9% -0.2 pp—
MGTXMeiraGTx Holdings plcLTM Mar 2026-120.0% +290.8 pp+619.2 pp
RGNXREGENXBIO Inc.LTM Mar 2026-261.2% -183.0 pp+138.5 pp
SANASana Biotechnology, Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding KRYS) -120.0%+53.9 pp+619.2 pp

Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0050.7M290.52M389.13M
Cost of Revenue003.09M20.06M28.77M
Gross Profit0047.61M270.45M360.36M
Gross Margin——93.9%93.1%92.6%
Research & Development27.88M42.46M46.43M53.57M58.05M
Selling, General & Admin40.39M77.74M98.4M113.69M146.74M
Operating Expenses68.28M145.2M157.33M204.76M199.06M
Depreciation & Amortization2.77M4.05M5.01M6.71M6.55M
EBITDA(65.31M)(116.14M)(92.22M)109.91M196.02M
EBITDA Margin——-181.9%37.8%50.4%
Operating Income(68.28M)(145.2M)(109.73M)65.7M161.3M
Operating Margin——-216.4%22.6%41.5%
Interest Income197K5.22M22.62M29.66M28.18M
Interest Expense1.49M0000
Other Income / Expenses(1.3M)5.22M122.62M29.66M28.18M
Income Before Tax(69.57M)(139.98M)12.9M95.36M189.47M
Pre-Tax Margin——25.4%32.8%48.7%
Income Tax Expense001.97M6.2M(15.36M)
Net Income(69.57M)(139.98M)10.93M89.16M204.83M
Net Margin——21.6%30.7%52.6%
EPS (Basic)(3.13)(5.49)0.403.127.08
EPS (Diluted)(3.13)(5.49)0.393.006.84
Weighted Avg Shares22.2M25.49M27.15M28.59M28.94M
Weighted Avg Shares (Diluted)22.2M25.49M27.75M29.74M29.95M

Krystal Biotech, Inc.

NASDAQ:KRYS

Intrinsic Alpha fair value

Locked

Current Price

$298.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.